Comparative Pharmacology
Head-to-head clinical analysis: NEPHROSCAN versus TECHNETIUM TC 99M DIPHOSPHONATE TIN KIT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NEPHROSCAN versus TECHNETIUM TC 99M DIPHOSPHONATE TIN KIT.
NEPHROSCAN vs TECHNETIUM TC 99M DIPHOSPHONATE-TIN KIT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Calcium trisodium pentetate (NEPHROSCAN) chelates gadolinium ions by forming a stable complex with the metal, thereby reducing the toxicity and enhancing elimination of gadolinium from the body. It acts as a decorporation agent for gadolinium.
Technetium Tc 99m diphosphonate is a bone-imaging agent that undergoes chemisorption onto hydroxyapatite crystals in bone. Uptake is increased in areas of high bone turnover, such as metastatic lesions, fractures, or inflammation.
1 to 5 mCi (37 to 185 MBq) as a single intravenous injection for renal imaging.
15-30 mCi (555-1110 MBq) IV single dose for bone scintigraphy.
None Documented
None Documented
Terminal elimination half-life: 1.6 hours in normal renal function; prolonged to >20 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life: 6–8 hours for the diphosphonate complex; clinical context: allows imaging up to 24 hours post-injection.
Renal: 95% as unchanged drug via glomerular filtration; no biliary/fecal excretion.
Renal: ~100% via glomerular filtration; no biliary/fecal elimination.
Category C
Category C
Diagnostic Radiopharmaceutical
Diagnostic Radiopharmaceutical